Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US FDA Lifts Clinical Hold of Astellas’ Pompe Gene Therapy
January 23, 2023
- Acoalan’s PIII Trial for Preeclampsia Due to Complete in July: Kyowa Kirin
January 23, 2023
- Meiji’s Stelara Biosimilar Shows Therapeutic Equivalence; Filing Eyed in 2023
January 23, 2023
- CSL Behring Launches App to Manage Hizentra Treatment Records
January 20, 2023
- Eisai Starts Stand-Alone Biz Operations in Israel
January 20, 2023
- Opdivo Outdistances Keytruda in 2022 with Sales Up 30 Billion Yen YOY: Encise
January 20, 2023
- Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
- Shionogi Commences New COVID Vaccine Trials for Children
January 18, 2023
- Chiome, China Firm Call off License Deal for Anti-TROP-2 Antibodies
January 18, 2023
- Chugai to End Sale of Joint Function Improving Agent Suvenyl in Japan
January 17, 2023
- Towa Set to Take on Legal Battle over Treakisym Patent
January 17, 2023
- Toray Rolls Out Remitch OD Tablets in South Korea
January 17, 2023
- Alzheimer’s Med Lecanemab Submitted in Japan: Eisai
January 16, 2023
- Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
- Estimated 11,867 Patients Given Xocova as of Jan. 5: Shionogi
January 16, 2023
- Ono, Monash University Ink GPCR Antibody Deal
January 16, 2023
- Skyrizi’s New IV Form Now Available for Crohn’s Disease
January 16, 2023
- Lucentis Biosimilar Now Approved for Diabetic Macular Edema
January 16, 2023
- Takeda’s Exkivity Approved in China for EGFR Exon 20+ NSCLC
January 16, 2023
- RaQualia’s Acid Reducer Tegoprazan Approved in Singapore
January 16, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…